ABSTRACT
In the past few years, it has become more normal to use data from clinical tests for other things. This is possible because many universities and the pharmaceutical business in the United States and Europe have decided to let people see their clinical study data. This is good for society because it moves medical research forward, but the rights of the people being studied must be respected. Subject data can be shared in two main ways: data about a single patient and clinical study reports. Each of these ways comes with its own set of risks. There is always a trade-off between how useful the info is and how likely it is that the person will be found again. It is very important to get the right mix. It is possible to figure out the amount of de-identification that is needed with the help of quantitative measures. New technologies may also offer other ways to balance risk and reward.
